The Municipal Corporation of Delhi’s (MCD) fight against dengue got a boost with an order from the Delhi High Court on Monday, which will ensure it smooth supply of biolarvicide that is sprayed to prevent mosquito breeding.
The court dismissed a challenge posed by a failed bidder Sumitomo Chemical India Private Ltd, a larvicide supplier, challenging the supply contract awarded to Biotech.
It alleged irregularities and contending that it had not been given an equal opportunity. After admitting the petition, the court had earlier stayed the procurement, throwing MCD’s anti-dengue operation haywire.
Later, the court modified the order and allowed procurement for only 15 days. and it had to be renewed every time.
Says MCD counsel Mini Pushkarna, “The court order is a big boost for MCD. With the stay removed and the court upholding our contract with Biotech, we are assured of smooth supply of larvicide essential to fight dengue. We had in fact run out of stock”.
“The petitioner did not satisfy the requisite conditions set by the MCD and the element of public interest, in certitude, tilts in favour of the decision making process of the MCD,” a Bench of Chief Justice.
Dipak Misra and Justice Manmohan said. The court upheld MCD’s argument that the medicine had to be procured in large quantity and one of the chief reason for not selecting Sumitomo was that their product had to be stored at a particular temperature, which was not possible.
“The purpose was to procure adequate quantity to control the spread of the disease which see geometric leap in the rainy season. It was incumbent on the part of the authorities to take efficient, responsible, expeditious and scientific precautionary measures to annihilate the spread”, the court said.